20. November 2009 09:18
Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.
[More]
85b72941-1acc-4d4b-b579-2fd76594d425|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Blood Pressure, Efavirenz, Erectile Dysfunction, Exercise, Headache, Heart Failure, Impotence, Low Blood Pressure, Nevirapine, Pfizer, Pulmonary Arterial Hypertension, Ritonavir, Stroke, Veno-Occlusive Disease, Vitamin K, Warfarin
16. November 2009 10:02
Gentium S.p.A. announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.
[More]
17. September 2009 08:13
Gentium S.p.A. (NASDAQ: GENT) today reported financial results for the second quarter ended June 30, 2009.
[More]
19. August 2009 08:30
Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.
[More]
b699f50b-ae11-4209-bca0-c7f390662d05|0|.0
Posted in: Drug Trial News
Tags: Cancer, Cell, Chemotherapy, Defibrotide, Dialysis, Hematology, Multiple Myeloma, Radiation Therapy, Stem Cell, Transplant, Veno-Occlusive Disease, Ventilator
26. May 2009 05:40
United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved Adcirca (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).
[More]
19. November 2008 22:18
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
[More] 
Subscribe